PT  - JOURNAL ARTICLE
AU  - SEIGO MINAMI
AU  - TAKASHI KIJIMA
AU  - KIYOSHI KOMUTA
AU  - TORU KUMAGAI
AU  - FUMIO IMAMURA
AU  - SOICHIRO YOKOTA
AU  - YOSHIKO TAKEUCHI
AU  - TAKESHI NAKATANI
AU  - ISAO TACHIBANA
AU  - ICHIRO KAWASE
TI  - Phase II trial of Pemetrexed Continuation – Maintenance after Carboplatin-based Induction in Untreated Non-squamous Non-small Cell Lung Cancer
DP  - 2013 Dec 01
TA  - Anticancer Research
PG  - 5535--5542
VI  - 33
IP  - 12
4099  - http://ar.iiarjournals.org/content/33/12/5535.short
4100  - http://ar.iiarjournals.org/content/33/12/5535.full
SO  - Anticancer Res2013 Dec 01; 33
AB  - Aim: We conducted a phase II study to evaluate the efficacy and safety of pemetrexed continuation-maintenance after carboplatin-based induction for advanced non-squamous non-small cell lung cancer (NSCLC). Patients and Methods: Thirty-four patients with advanced or recurrent non-squamous NSCLC received carboplatin (area under the concentration-time curve 6 mg/ml×min) plus pemetrexed (500 mg/m2) on day 1 tri-weekly. After four cycles of induction, patients without disease progression received pemetrexed maintenance until disease progression or unacceptable toxicity. Results: Twenty-five patients completed induction and 22 received maintenance. The 1-year survival, objective response and disease control rates were 70.3%, 32.4% and 88.2%, respectively. The median progression-free survival and overall survival of all patients were 5.2 and 23.3 months. The incidental rates of grade 3 or more severe adverse events were low. Conclusion: This regimen appears to be an appropriate option for chemonaïve patients with advanced non-squamous NSCLC.